A PI[INVESTIGATOR_24023]:  14-146H  
Sponsor -Investigator:  Christopher Hartnick, MD  
Funded By: [CONTACT_24084][INVESTIGATOR_24024]:  Inspi[INVESTIGATOR_24025]:  G140209  
Device has prior FDA approval (PMA and IDE P130008, G080122)  
NCT 02344108  
 
Version Number:  v.9. 5; 08 May  2020 
 
Document History Sum mary  
Version #  Version Date  
9.5 08 May 2020  
9.0 05 Jul  2019 
8.0 29 Mar 2018  
1.0 – 7.0 2014 – 2018 
 
 
  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 2 of 32 Table of Contents  
Acronyms & Abbreviations ................................ ................................ ................................ ................................ ...............  5 
Schema  ................................ ................................ ................................ ................................ ................................ ..................  6 
Protocol Summary  ................................ ................................ ................................ ................................ ..............................  7 
Principal Investigator [INVESTIGATOR_24026]  ................................ ................................ ................................ ..............................  9 
1 Introduction  ................................ ................................ ................................ ................................ .............................  10 
1.1 Study Rationale  ................................ ................................ ................................ ................................ ...............  10 
1.2 Background  ................................ ................................ ................................ ................................ ......................  10 
2 Objectives  ................................ ................................ ................................ ................................ ................................ . 11 
2.1 Primary Objectives  ................................ ................................ ................................ ................................ .........  11 
2.2 Secondary Objectives  ................................ ................................ ................................ ................................ ..... 11 
3 Study Design  ................................ ................................ ................................ ................................ ............................  11 
4 Patient Selection  ................................ ................................ ................................ ................................ ......................  11 
4.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ............  11 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ...........  12 
4.3 Strategies for Recruitment and Retention ................................ ................................ ................................ ... 12 
5 Study Procedures  ................................ ................................ ................................ ................................ ....................  13 
5.1 Schedule of Events  ................................ ................................ ................................ ................................ .........  13 
5.2 Assessment s ................................ ................................ ................................ ................................ .....................  13 
5.2.1  Physical Exam with Functional Tongue Exam  ................................ ................................ ................  13 
5.2.2  Surgical Consultation  ................................ ................................ ................................ ............................  14 
5.2.3  Quality of Life Questionnaires  ................................ ................................ ................................ ............  14 
5.2.4  In-Lab Titration Sleep Study: Polysymnography (PSG)  ................................ ................................ . 14 
5.2.5  Drug Induced Sleep Endoscopy (DISE)  ................................ ................................ ...........................  15 
5.2.6  Device Check  ................................ ................................ ................................ ................................ .........  15 
5.3 Study Visits  ................................ ................................ ................................ ................................ ......................  16 
5.3.1  Screening / Baseline  ................................ ................................ ................................ ..............................  16 
5.3.2  Surgery  ................................ ................................ ................................ ................................ .....................  16 
5.3.3  Device Activation and Initial Titration  ................................ ................................ ..............................  17 
5.3.4  Follow -up Study Visits  ................................ ................................ ................................ .........................  17 
5.3.5  Unscheduled Visits  ................................ ................................ ................................ ................................  17 
5.4 Concomitant Medications and Procedures  ................................ ................................ ................................  18 
5.5 Participant Discontinuation / Withdrawal from the Study  ................................ ................................ ..... [ADDRESS_23121] to Follow -up ................................ ................................ ................................ .............  19 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 3 of 32 6 Study Device  ................................ ................................ ................................ ................................ ............................  20 
6.1 Device Components ................................ ................................ ................................ ................................ ....... 20 
6.1.1  Implan table Pulse Generator (IPG)  ................................ ................................ ................................ ... [ADDRESS_23122] Storage and Stability  ................................ ................................ ................................ ........................  22 
6.3.1  IPG ................................ ................................ ................................ ................................ ..........................  22 
6.3.2  Leads  ................................ ................................ ................................ ................................ ........................  22 
7 Risks and Benefits  ................................ ................................ ................................ ................................ ...................  23 
7.1 Known Potential Risks  ................................ ................................ ................................ ................................ .. 23 
7.1.1  Risks of Screening Procedures  ................................ ................................ ................................ ............  23 
7.1.2  Risk of Implantation Surgery  ................................ ................................ ................................ ...............  23 
7.1.3  Pregnancy Risks  ................................ ................................ ................................ ................................ ..... 25 
7.1.4  Psychosocial (non -medical) Risks  ................................ ................................ ................................ ....... [ADDRESS_23123]  ................................ ................................ ................................ ..............  26 
8.2 Research monitor  ................................ ................................ ................................ ................................ ............  26 
8.3 Regular Site Monitoring  ................................ ................................ ................................ ................................ . 26 
8.4 Adverse Event Monitoring and Reporting  ................................ ................................ ................................ . 27 
8.4.1  AE Definitions for Investigator Classification  ................................ ................................ .................  27 
8.4.2  Adverse Event Reporting  ................................ ................................ ................................ .....................  28 
8.4.3  Anticipated Adverse Device -Related Events  ................................ ................................ ....................  29 
8.4.4  Technical Observation/Device Deficiencies  ................................ ................................ ....................  [ADDRESS_23124] Death  ................................ ................................ ................................ ................................ .........  30 
9 Statistical Considerat ions ................................ ................................ ................................ ................................ ....... 30 
9.1 Primary endpoint(s) or outcome measure(s)  ................................ ................................ ..............................  30 
9.2 Secondary endpoints or outcome measure(s)  ................................ ................................ ............................  30 
9.3 Sample Size Determination  ................................ ................................ ................................ ...........................  31 
9.4 Analysis Population  ................................ ................................ ................................ ................................ ........ 31 
9.5 Effectiveness Analysis (if applicable)  ................................ ................................ ................................ ..........  [ADDRESS_23125]  ................................ ................................ ................................ ... 31 
10.2 Informed Consent  ................................ ................................ ................................ ................................ ..........  31 
10.2.1  Inclusion of Minors  ................................ ................................ ................................ ...............................  31 
10.2.2  Inclusion of Persons not Competent to Consent  ................................ ................................ ............  32 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 4 of 32 10.2.3  Non-English Speaking Subjects  ................................ ................................ ................................ ..........  32 
10.3 Statement of Compliance  ................................ ................................ ................................ ..............................  32 
References  ................................ ................................ ................................ ................................ ................................ ..........  32 
  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 5 of 32 Acronyms & Abbreviations  
Term  Meaning  
AE Adverse Event  
AHI Apnea/Hypopnea Index  
BMI Body Mass Index  
CFR Code of Federal Regulations  
CMP  Clinical Monitoring Plan  
CRF Case Report Form  
DHHS  Department of Health and Human Services  
DISE  Drug Induced Sleep Endoscopy  
DSMB  Data Safety Monitoring Board  
eCRF  Electronic Case Report Forms  
ESS Epworth Sleepi[INVESTIGATOR_24027]’s Brochure  
ICH International Conference on Harmoniz ation  
IDE Investigational Device Exemption  
IPG Implantable Pulse Generator  
IRB Institutional Review Board  
MEEI  [LOCATION_005] Eye and Ear  
MOP  Manual of Procedures  
OHRP  Office for Human Research Protections  
OSA  Obstructive Sleep Apnea  
OSA -[ADDRESS_23126] Operating Procedure  
UP Unanticipated Problem  
 
  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 6 of 32 Schema  
 
  

  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 7 of 32 Protocol Summary  
Title:  A pi[INVESTIGATOR_24028] s yndrome and obstructive sleep apnea  
Investigational Device :  Inspi[INVESTIGATOR_1312]® Upper Airway Simula tion System,  Model 3028 IPG  (previously 
Model 3024 IPG)  
Study Design:  This is a multicenter, prospective, single -arm study of an implantable device 
for the treatment of obstructive sleep apnea in patients with Down 
syndrome and previous treatment of adenotonsillectomy .  
Accrual Goal:  Up to 42  
Patient Population:  Subjects  aged 10 -21 with Down syndrome and Obstructive Sleep Apnea 
with previous treatment of adenotonsillectomy .  
Inclusion / Exclusion 
Criteria:  Inclusion Criteria:  
All subjects that participate in this study must meet the following 
criteria:  
1. Children and young adults  with Down syndrome  
2. Age 10 -21 year s  
3. Prior adenotonsillectomy  
4. Moderate to severe OSA (AHI >10, AHI <50, no more than 25% 
AHI attributable to central events) based on prior in -lab PSG 
performed after adenotonsillectomy  
5. Subjects must have either tracheotomy or be ineffectively treated 
with CPAP due to noncompliance, discomfort, un -desirable side 
effects, persistent symptoms despi[INVESTIGATOR_24029], or refusal to 
use the device.  
6. Children and their parents must be willing to have stimulation 
hardware  permanently implanted, and be willing to participate in 
follow -up visits, postoperative PSG, and questionnaire completion.  
7. Children’s parents must complete a questionnaire confirming that 
their child is capable of communicating feelings of pain or 
discomf ort.  They must also confirm they are able to assess their 
child for adverse effects related to device implantation.   
8. Children and their parents must be proficient in English.  
Exclusion Criteria:  
The presence of any of the following will exclude a potent ial subject 
from participation:  
1. BMI>the 95th percentile for age  
2. Any anatomic finding on physical exam  or DISE  that would 
compromise the performance of stimulation (e.g. co ncentric soft 
palate collapse)  
3. Other medical conditions resulting in medical instab ility (e.g. 
congestive heart failure, recent open heart surgery, 
immunosuppression, or chronic lung disease or aspi[INVESTIGATOR_1516])  
4. Presence of another medical condition requiring future magnetic 
resonance imaging (MRI) of the chest  
5. Patients with another implantab le device which could interact 
unintentionally with the Inspi[INVESTIGATOR_24030]  
6. Any contraindication for general anesthesia  
7. Life expectancy < 12 months  
8. Inability to communicate pain or discomfort to their 
caretaker/parent, based on parental or investigator assessme nt 
9. History of bleeding or clotting disorders and those on blood 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 8 of 32 thinning or NSAID medications for the week prior implantation 
surgery.  Subjects will be asked to refrain from the use of NSAIDS 
for two weeks after the implantation or any revision surgeries.  
10. Taking muscle relaxant medication  
11. Female subjects who are pregnant or plan to become preg nant 
during the study period.  
12. Subjects deemed unfit for participation by [CONTACT_24085].  
Objectives:  Primary Objectives:  
1. Evaluate device related  serious adverse events from implant to 12 
month follow -up 
2. Evaluate device -related adverse events from implant to 12 month 
follow -up 
Secondary Objectives:  
1. Therapy efficacy measured by [CONTACT_24086] -18 and ESS at 12 month 
follow -up  
2. Therapy efficacy measured by [CONTACT_24087] 12 month follow -up 
3. Objective mean weekly usage data obtained from the physician 
programmer  at the 12 month visit  
Investigational 
Intervention:  All enrolled patients will undergo device implantation surgery  of the 
investigational device , device activation, and several follow -up visits.  
 
  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 9 of 32 Principal Investigator [INVESTIGATOR_24031]:  A pi[INVESTIGATOR_24032] s yndrome and obstructive sleep apnea  
 
Protocol #: 14 -146H  
 
Protocol Version Number/ Date: Version 9.0; [ADDRESS_23127] the study as described in the protocol and in accordance with the relevant 
laws/regulations and standards outlined in the Clinical Trial Agreement.  
 
 
 
______________________________ _________________________  
Name  
 
 
 
______________________________ _________________________  
Signature  
 
 
 
_____________________________  
Date  
  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 10 of 32 1 Introduction  
1.1 Study Rationale  
Obstructive sleep apnea (OSA) affects up to 1% of the general pediatric population and is associated with 
adverse behavior and quality of life, as well as long term cardiopulmonary system complications.  Trisomy 21 
(Down syndrome) is the most common chromo somal disorder, with an incidence of approximately [ADDRESS_23128] a higher incidence of OSA than the general pediatric 
population, with rates of 30 -60%, resulting in increased morbidity and decreased quality of life for affected 
individuals.  In children, adenoton sillar hypertropy  is often a contributing factor to OSA, and 
adenotonsillectomy is a first line treatment.  Children with Down syndrome often undergo T&A for 
obstructive sleep apnea; however 30 -50% will have persistent obstructive sleep patterns requiring continuous 
positive pressure airway support (CPAP) or tracheotomy. Persistent obstruction is attributed to anatomic and 
physiologic differences in this population, including reduced muscular tone, macroglossi a, maxillary 
hypoplasia, and lingual tonsil hypertrophy.  This pi[INVESTIGATOR_24033]® Upper 
Airway Simulation System, Model 3024 IPG (now Model 3028 IPG; see below), which has already been 
approved for use in adults with OSA, can be safely implanted and used in the treatment of adolescents and 
young adults with Down Syndrome.  
 
The Inspi[INVESTIGATOR_24034] (15 ≤ Apnea Hypopnea - AHI ≤ 65) in 
adult patients who are not effectively treated by C PAP. The Inspi[INVESTIGATOR_24035]:  
 Inspi[INVESTIGATOR_24036], Model 3024 (Implantable Pulse Generator, IPG) and any 
subsequent iteration thereof that are approved under P130008 for the treatment of obstructive sleep apnea which are 
listed below and updated as needed via protocol mod ifications submitted to the FDA.  Note: Inspi[INVESTIGATOR_24037] 3028 
IPG received FDA approval on May 5, 2017 and replaces Model 3024 IPG.  
 Inspi[INVESTIGATOR_24038], Model 4063 (stimulation lead)  
 Inspi[INVESTIGATOR_24039], Model 4323 (sensing lead)  
 External programmers used with the system are:  
o Inspi[INVESTIGATOR_24040], Model 2740 (physician programmer)  
o Inspi[INVESTIGATOR_24041], Model 3032 (patient programmer)  
1.2 Background  
A global pi[INVESTIGATOR_16076] (the STAR trial) and three feasibility studies have been performed with the Inspi[INVESTIGATOR_24042].  The first feasibility study (Inspi[INVESTIGATOR_1312] 1) implanted the Inspi[INVESTIGATOR_1312] I system in [ADDRESS_23129] patient  (1), the first 6 p atients  (2), and later for the 
first 20 implanted patients  (3).  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 11 of 32 2 Objectives  
2.1 Primary Objectives  
1. Evaluate device -related serious adverse events from implant to 12 month follow -up 
2. Evaluate device -related adverse events from implant to 12 month follow -up 
 
2.2 Seco ndary Objectives  
1. Efficacy of HGN stimulation as measured by [CONTACT_24086] -18 and ESS at 12 month follow up  
2. Efficacy of HGN stimulation as measured by [CONTACT_24087] 12 month follow -up 
3. Objective mean weekly usage data obtained from the physician programmer  at 12 month follow -up 
 
3 Study Design  
The study is a multi -center, prospective, single -arm study conducted under a common implant and follow -up 
protocol.  Fifty adolescents and young adults (10 -21 years of age) with Down syndrome with moderate to 
severe obstructive sleep  apnea after adenotonsillectomy.  
 
After providing informed consent, p atients (with input from their parents /guardians as appropriate)  will be 
screened according to the eligibility criteria below.  Subjects will then undergo preoperative evaluation with an 
in-lab polysomnogram (PSG) ( if available, an in -lab PSG per formed within 18  months prior to study 
consent may be used) , evaluation by a pediatric otolaryngology surgeon, and drug induced sleep endoscopy 
(DISE)  (If available, a DISE that was performed withi n 18 months of the study consent may be used)  
to ensure all inclusion and exclusion criteria are met.    
 
Subjects meeting eligibility criteria will then undergo hypoglossal nerve implantation of the Inspi[INVESTIGATOR_1312]® Upper 
Airway Simulation System. Surgery will be performed by [CONTACT_24088] a 
training program for the Inspi[INVESTIGATOR_24030].   
 
Subjects will then adhere to a follow -up schedule.  The device will be activated and settings titrated during an 
in-lab sleep study [ADDRESS_23130] meet the following criteria:  
1. Children and young adults  with Down s yndrome  
2. Age 10 -21 year s  
3. Prior adenotonsillectomy  
4. Moderate to severe OSA (AHI >10, AHI <50, no more than 25% AHI attributable to central 
events) based on prior in -lab polysomnography per formed after adenotonsillectomy  
5. Subjects must have either tracheotomy or be ineffectively treated with CPAP due to noncompliance, 
discomfort, un -desirable side effects, persistent symptoms despi[INVESTIGATOR_24043] e, or refusal to use 
the device.  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23131] stimulation hardware permanently implanted, and 
be willing to participate in follow -up visits, postoperative polysomnography, and questionnaire 
completion.  
7. Children’s paren ts must complete a questionnaire confirming that their child is capable of 
communicating feelings of pain or discomfort.  They must also confirm they are able to assess their 
child for adverse effects related to device implantation.   
8. Children and their pa rents must be proficient in English for this pi[INVESTIGATOR_24044], as well as have the ability to communicate with all staff, at all 
times, regarding any questions about participation or concerns about t his device.  In further studies, 
we plan to expand study materials and resources in order to include patients who are non -English 
speaking. Given the small scale of this pi[INVESTIGATOR_799], we feel initial exclusion of non -English speaking 
individuals should not adversely affect applicability of our results to the general population, nor 
should it prevent all qualified patients from eventual access to device implantation.  
 
4.[ADDRESS_23132] fro m participation:  
1. BMI>the 95th percentile for age  
2. Any anatomic finding on physical exam or drug induced sleep endoscopy (DISE) that would 
compromise the performance of stimulation (e.g. concentric soft palate collapse),  
3. Other medical conditions resulting  in medical instability (e.g. congestive heart failure, recent open 
heart surgery, immunosuppression, or chro nic lung disease or aspi[INVESTIGATOR_1516])   
4. Presence of another medical condition requiring future magnetic reson ance imaging (MRI) of the 
chest  
5. Patients with  another implantable device which could interact unintent ionally with the Inspi[INVESTIGATOR_24030]  
6. Any contraindication for general anesthesia  
7. Life expectancy < 12 months  
8. Inability to communicate pain or discomfort to their caretaker/parent, based on parental or 
investigator assessment  
9. History of bleeding or clotting disorders and those on blood thinning or NSAID medications for the 
week prior implantation surgery.  Subjects will be asked to refrain from the use of NSAIDS for two 
weeks after the implantation or any r evision surgeries.  
10. Taking muscle relaxant medication  
11. Female subjects who are pregnant or plan to become pregnant during the study period.  All female 
subjects aged 11 and up will undergo urine beta -HCG testing on the day of procedures requiring 
general ane sthesia (DISE, implantation, and any other unanticipated surgical procedures related to 
implantation).  Subjects who are positive will not undergo surgical implantation or procedures under 
general anesthesia.  
12. Subjects deemed unfit for participation by [CONTACT_24089].  
 
4.3 Strategies for Recruitment and Retention  
Up to forty-two (42) subjects will be recruited from the practices of participating investigators as well as 
referrals to these investigators ; however, the study may stop after e nrollment of only 40 subjects if some 
participants choose not to undergo surgery . Subjects who are deemed appropriate for the study (e.g. by 
[CONTACT_24090]) during their initial contact [CONTACT_24091]. Subjects will be given the opportunity to ask any questions and if desired, the 
consent forms so they can review the study away from study staff. Subjects will also be given contact 
[CONTACT_24092] s tudy team should they have further questions once they leave the clinic or hospi[INVESTIGATOR_307].   
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 13 of 32 Furthermore, if enrollment for a particular group does not seem adequate, then steps will be taken to 
promote increased enrollment of the under -represented group. Such steps include: 1) we will contact [CONTACT_24093]; 2); we will reach out to local, state, regional, and national Down syndrome gro ups, and 
3) an additional study site may be added.  
5 Study Procedures  
5.1 Schedule of Events  
 Visit 0  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  
 Screening 
/ Baseline  Implant 
Surgery  Device 
Activation 
(1M post -op) 2M (5)  6M (5)  12M (5)  
Eligibility  X      
Informed Consent  X (1)  X (2)      
Surgical Consultation  X      
Limited Physical Exam  X  X X X X 
Functional Tongue Exam  X X X X X X 
Medication Reconciliation  X  X X X X 
QOL (ESS, OSA -18) X     X 
In-Lab PSG  X (3)   X X X X 
DISE  X (3)       
Urine Pregnancy  X (6)       
Surgery   X     
Device Check    X X X X 
AE Review   X X X X X 
(1) Informed Consent may be done in 2  stages  if approved by [CONTACT_8236]’s local IRB .  For patients 
who are considering participation but do not have the funds to travel to the study site for pre -
screening, a remote consent may be conducted (if IRB approved) to allow for review of medical 
records for the purpose of screening for the study.  Stage 2 will be in person consent for participation 
in the study.   In person consent for participation in the study is required for all subjects.  
(2) Separate surgical consent is obtained as part of standard of care  based on institutional requirements .  
(3) If In-lab PSG and DISE done  as part of standard of care within 18  months of consent, these tests do 
not need to be repeated.  
(4) 4-[ADDRESS_23133] activation  
(5) +/- 30 days  
(6) Done for females age [ADDRESS_23134] -implant follow -up visits, the exam will assess: appearance of surgical wound at the neck, facial 
nerve function, appearance of surgical wound on the chest, and tongue function. The tongue function exam 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23135].  A digital 
pi[INVESTIGATOR_24045] (optional).   
 
The subject will be disqualified for implant if any pronounced anatomical abnormalities exist (e.g., tonsil size 
of 3 or 4) that, in the Investigator’s opi[INVESTIGATOR_1649], preven t effective use or assessment of the Inspi[INVESTIGATOR_24046].  If a 
subject is excluded on the basis of Investigator opi[INVESTIGATOR_1649], the specific reason for exclusion will be documented.  
 
5.2.3 Quality of Life Questionnaires  
[IP_ADDRESS]  Epworth Sleepi[INVESTIGATOR_7110] (ESS)  
The Epworth Sleepi[INVESTIGATOR_1651] s Scale ( ESS) is a validated, self -report instrument that rates a subject’s tendency to fall 
asleep in ei ght common daily situations (4).   The ESS Scale has been validated primarily in OSA.  It is used to 
measure excessive daytime sleepi[INVESTIGATOR_008], and is often utilized before and after the administration of treatment to 
document improvement of symptoms.   
 
The ESS will be  completed during the Baseline visit and 12 -month follow -up. 
[IP_ADDRESS]  Obstructive Sleep Apnea -18 (OSA -18) 
The Obstructive Sleep Apnea -18 (OSA -18) is a survey given to caregivers to assess how sleep disordered 
breathing effects on the daily life of their children. It contains 18 questions related to 5 domains: 1) sleep 
disturbance, 2) physical suffering, 3) emotional distress, 4) day time problems, a nd 5) caregiver concerns. The 
survey has been shown to have good reliability and validity. The survey takes 5 to 10 minutes to complete.  
 
A change score < 0.5 represents a trivial change, 0.5 -0.9 indicates a small change, 1.0 -1.4 demonstrate a 
moderate ch ange, and ≥ 1.5 indicates a large change (5).  
 
The OSA -18 will be completed at the Baseline visit and 12 month follow -up. 
 
5.2.4 In-Lab Titration Sleep Study: Polysymnography ( PSG) 
Polysomnography will be conducted using standard techniques in the sleep laborato ry.  The AASM 
(American Association of Sleep Medicine) Manual of Scoring Sleep, 2007 (6) is used as a guideline for rules , 
terminology and technical specifications for the PSG study.  Briefly, the following list of recordings will be 
collected.  
1. Three chann els of electroencephalogram  
2. Chin electromyogram  
3. Two channels of electrooculogram  
4. A single bipolar modified Lead II for electrocardiogram  
5. Chest and abdomen belts for  respi[INVESTIGATOR_24047]  
6. One oronasal thermal sensor to detect the absence of airflow for apnea  
7. One nasal pressure transducer for detection of airflow for hypopnea   
8. One finger oximeter to continuously monitor arterial oxygen saturation  
9. One position sensor to electronically deter mine position (supi[INVESTIGATOR_050], left, right, prone), or a means for 
documenting position  
10. One leg electromyogram to record leg movements  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23136] 
sleep during the PSG.   
 
Note: If a PSG was completed within [ADDRESS_23137] report AHI 
and > 25% of AHI attributable to central apnea as these are part of eligibility criteria.  
 
5.2.5 Drug Induced Sleep Endoscopy (DISE)  
Sleep endoscopi[INVESTIGATOR_24048].  Sleep endoscopy is typi[INVESTIGATOR_24049].  A digital video of the sleep endoscopy w ill be 
recorded.  Continuous monitoring with electrocardiogram and oxygen saturation is performed.  Induction of 
artificial sleep is achieved by [CONTACT_24094] (or physician with equivalent training) by [CONTACT_24095]/ or midazolam.   Anesthesia is titrated by [CONTACT_24096] a level of light sedation 
such that the subject is arousable upon vocal stimulation.  
 
Anatomical collapse is evaluated at the level of the palate, oropharynx, tongue base, and epi[INVESTIGATOR_24050].  The 
degree of o bstruction is characterized at each level as complete, partial, or none.  The type of collapse is also 
characterized at each level as concentric, antero -posterior (A -P) or originating from the lateral wall.  Subjects 
with complete concentric collapse at th e level of the soft palate are not eligible for implant and exited from 
the study during pre -implant screening.   
 
If a DISE is performed as a sta ndard -of-care procedure within 18  months  prior to consent , and results 
(documented in the medical history) cle arly state that subject did not have complete concentric collapse at the 
level of the soft palate, then the implant may be scheduled.  
 
A DISE must be performed after enrollment and before implan t, if one did not occur within 18 months prior 
to signing con sent.  The DISE may be performed immediately prior to the implant (during the same 
procedure as the implant).  This allowance is intended to prevent subjects from having to undergo an 
additional DISE procedure at centers where DISE is a standard assessment , when the DISE is likely to match 
a prior DISE result.  
 
All video recordings of the DISE procedures will be uploaded electronically  both to a secure hospi[INVESTIGATOR_307] -hosted 
file transfer system  and to a secure Inspi[INVESTIGATOR_1312] -hosted website.  The video is then review ed by a team of three 
specialist physicians , including the sponsor -investigator; at least two of the reviewing physicians must agree 
the subject is an appropriate candidate for surgery .  The three doctors are [CONTACT_24112] from 
[LOCATION_005] Eye a nd Ear Infirmary, [CONTACT_24113]  from University of Pi[INVESTIGATOR_24051]. 
Raj Dedh ia from  the University of Pennsylvania .  If a DISE is to be performed just prior to surgery in order 
to decrease the number of times a subject is anesthetized, th e physician reviewers will be alerted and available 
via phone to review the DISE in real -time.  The decision of the physicians was previously documented via e -
mail but as of version 9 of the protocol, a worksheet will be completed and sig ned by [CONTACT_456] -
investigator; any additional documentation provided by [CONTACT_24097].  
 
5.2.[ADDRESS_23138] use of the device will be 
verified.  In addition, stimulation threshold testing may be performed where by [CONTACT_24098] ..  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 16 of 32 During sensor testing, the physician programmer displays the respi[INVESTIGATOR_24052], as well as the timing 
of stimulation pulses.  Adjustmen ts can be made to the device sensing parameters (sensing thresholds and 
refractory periods) to synchronize stimulation with respi[INVESTIGATOR_1516].  For example, if stimulation starts late, after 
the start of inspi[INVESTIGATOR_1516], the sensing parameters are made more sensitiv e to the start of inspi[INVESTIGATOR_1516].  If the end 
of inspi[INVESTIGATOR_24053], then the sensing parameters detecting the end of inspi[INVESTIGATOR_24054].   
 
The device should be interrogated at the beginning of the subject’s follow -up; and any progr amming changes 
that occur during the follow -up should be documented in the Device Check CRFs.  Information will also be 
collected about the subject’s use of the device since the last follow -up at each visit.  Information concerning 
any difficulties in oper ating the system, and sudden changes in the effects of the system, will be documented.   
 
Note: the Investigator will have received training on how to perform device programming, and will have the 
programmer technical manual available for reference.  There fore, detailed programming steps are not 
included in this protocol.  
 
5.3 Study Visits  
5.3.1 Screening  / Baseline  
Screening and Baseline activities may o ccur over several clinic visits, and may include information and/or 
tests that  were performed locally within 18  months prior to signing consent.  After consent is obtained (either 
in person consent to participate in the study or, if allowed by [CONTACT_1036], remote consent for screening), 
medical records including the PSG  will be reviewed by [CONTACT_24099]  [INVESTIGATOR_24055] [ADDRESS_23139] placement of the device.  The device will remain off (turned “off,” voltage set 
to = 0) until the activation and titration appointments scheduled approx imately [ADDRESS_23140] may undergo attempted implantation of the device, but the surgeon may be unsuccessful in placing 
the device.  If one or both leads cannot be placed, the incision (s) will be closed, and the stimulator will not 
be implanted.  The subject will return for a follow -up visit (usually within 14 days, but no greater than 30 days 
after attempted implantation). If no adverse event has occurred  related to the surgery, the subject may be 
released from the study after the follow -up visit.  
 
5.3.[ADDRESS_23141] ate subjects and families, this may be done at their local ENT. No data will be collected at this 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 17 of 32 visit.  Subjects and their families will be instructed to call the study doctor if there are any issues noted at this 
visit or at any time during the study.  
 
5.3.4 Device Activation and Initial Titration  
At approximately 1 month  (± 14 days)  after implantation (or 1 month  ± [ADDRESS_23142] resolved) , subjects will be seen at the office and on the same day be scheduled for an in -lab PSG.  
The surgeon will reassess the wound, perform a functional  tongue exam, review and update  the medication 
list, and check the device.  The device will then be turned on and voltage adjusted to confirm that it is 
functioning.  Vo ltage will be turned down to 0. The subject will then undergo overnight in -lab PSG and 
settings on  the device will be titrated.   
 
5.3.5 Follow -up Study Visits  
[IP_ADDRESS]  2 Month Follow -Up Visit  
Appr oximately 2 months (± 30 days) after implantation, the subject will be evaluated by [CONTACT_11065].  A 
limited physical exam, including functional tongue exam, will be performed. Medication reconciliation will be 
performed.  Any adverse events will be documented and submitted.  The OSA -[ADDRESS_23143] will then undergo in -lab PSG  and if 
necessary, further titration. This in -lab PSG may occur within 2 weeks of the follow -up visit or as 
appointments are available at each site’s sleep lab. However, all efforts should be made to keep the follow -up 
clinic visit and in -lab PSG as close as possible.  
 
[IP_ADDRESS]  6 Month Follow -up Visit  
Approximately 6 months (± 30  days)  after implantation, the subject will be evaluated by [CONTACT_11065].  A 
limited physical exam, including functional tongue exam, will be performed. Medication reconciliation will be 
performed.  Any adverse events will be documented and submitted.  The OSA -[ADDRESS_23144] will then undergo in -lab PSG  and if 
necessary, further titration. This in -lab PSG may occur within 2 weeks of the follow -up visit or as 
appointments are available at each site’s sleep lab. However, all efforts should be made to keep the follow -up 
clinic visit and in -lab PSG as close as possible . 
 
[IP_ADDRESS]  12 Month Follow -up Visit  
Appro ximately 12 months (± 30 days) after implantation, the subject will be evaluated by [CONTACT_11065].  A 
limited physical exam, including functional tongue exam, will be performed. Medication reconciliation will be 
performed.  Any adverse events will be documented and submitted.  The OSA -[ADDRESS_23145] will then 
undergo in -lab PSG  and if necessary, further titration. This in -lab PSG may occur within 2 weeks of the 
follow -up visit or as appointments are available at each site’s sleep lab. However, all efforts should  be made to 
keep the follow -up clinic visit and i n-lab PSG as close as possible.  
 
5.3.[ADDRESS_23146] ing troub leshooting procedures.  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 18 of 32 5.4 Concomitant Medications and Procedures  
Subjects will continue their home medications during participation in the study, with the exception of 
NSAIDs or dietary supplements that increase the risk of bleeding in the immediate perioper ative period ([ADDRESS_23147] -implantation).  Subjects will receive standard anesthetics and 
postoperative pain medications.  Medication logs will be reviewed, updated, and documented at each 
postoperative visit.  General anesth esia in the Down syndrome population may cause increased risk of airway 
obstruction and bradycardia intraoperatively, as well as increases the risk of emergence agitation in the 
immediate postoperative period.  This will be discussed with families during t he consent process, as well as 
on the day of procedures when anesthesiology obtains anesthesia consent.  
 
5.5 Participant Discontinuation / Withdrawal from the Study  
5.5.1 Discontinuation of Device  
Discontinuation of device use or choosing not to use the device does not mean discontinuation from the 
study, and any remaining study procedures should be completed as indicated by [CONTACT_4690].  If a 
clinically significant finding is identified (including, but not limited to changes from baseline) after enrollment, 
the investigator or qualified designee will determine if any change in participant management is needed. Any 
new clinically relevant finding will be reported as an adverse event (AE).  
 
5.5.[ADDRESS_23148].  
An investigator may discontinue or withdraw a participant from the study for the following reasons:  
 Pregnancy  
 If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant  
 Disease progression which requires discontinuation of the study intervention  
 If the participant meets an exclusion criterion (either new ly developed or not previously recognized) 
that precludes further study participation  
 
The reason for participant discontinuation or withdrawal fro m the study will be recorded . Subjects who sign 
the informed consent form, and are implanted , and subsequentl y withdraw, or are withdrawn or discontinued 
from the study, will  be replaced.  
 
The DSMB may also determine whether participants should continue in the study as planned, proceed with 
modifications, or have their participation terminated.  The justification  to terminate a subject’s participation 
may be due to the DSMB’s analysis that there is a concern for the subject’s safety or the subject’s ability to 
comply with study requirements.  
 
5.5.3 Device Failure, Revision, and Explant  
[IP_ADDRESS]  System Revision  
If the performance  of the Inspi[INVESTIGATOR_24056], a replacement or 
adjustment to one or more components of the Inspi[INVESTIGATOR_24030] (IPG, stimulation lead, or sensing lead) may be 
considered.  Specific guidance on removal or adjustment of impl anted components is contained in system 
manuals.  The decision for replacement must be reviewed w ith the device manufacturer .  Explanted system 
components  must be returned to the device manufacturer .  If the therapy is abandoned, device removal will 
be discussed with the subject as described in the following section.  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 19 of 32 [IP_ADDRESS]  System Explant  
The system may be explanted at any time during the study.  Subjects may request that their device be 
removed due to discomfort of components, infection, erosion, or subject m ay not respond to the therapy and 
elect removal.  
If the device is removed, the following CRFs must be completed.  
 Adverse Event Form  
 Updates to Medication Log  
 
[IP_ADDRESS]  System Explant Post -Op Check  
Following removal of the device or components, the subject will be seen 1 week (4 -14 days) after revision or 
removal to check the subjects’ well -being and examine the wound post -operatively.   
The following CRFs will be completed during the Post -Op check:  
 Physical Exam  
 Updates to Medication Log  
 Adverse Event Form (if applicable)  
 
[IP_ADDRESS]  Disposition of Device Following Study Withdrawal  
Subjects who withdraw from the study will need to discuss with their physician the disposition of their 
implanted system.  Upon withdrawal from the study, the subject may continue with the use o f the therapy, 
and should consult with the physician regarding long -term management with the therapy.  
 
Investigators should discuss expectations with subjects who withdraw from the study including:  
 MRI imaging of the chest may NOT be performed when system components are implanted.  
However, MRI imaging of the head and extremities may be performed as needed a ccording to 
specific parameters.  
 Inform personal physicians, consulting physicians, or dentists that a stimulation system is implanted.  
 Carry the Inspir e Medical Systems patient ID card at all times.  
 Consult the study p hysician or the device manufacturer  if the following medical treatments are 
required:  dental procedures requiring a drill, surgery with electrocautery, irradiation therapy, 
lithotripsy, RF -ablation, high output ultrasonic therapy, other implantable stimulation therapy, or 
defibrillation.   
 
5.5.[ADDRESS_23149] be taken if a participant fails to return to the clinic for a required study visit:  
 The site will attempt to contact [CONTACT_24100] -weekly for 3 
months and counsel the participant on the importance of maintaining the assigned visit schedule and 
ascertain if the participant wishes to and/or should continue in the study.  
 Before a participant is deemed lost to follow -up, the inve stigator or designee will make every effort 
to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified 
letter to the participant’s last known mailing address or local equivalent methods). These contact 
[CONTACT_24101]’s medical record or study file.  
 Should the participant continue to be unreachable, he or she will be considered to have withdrawn 
from the study with a primary reason of lost to follow -up. 
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 20 of 32 6 Study Device  
The Inspi[INVESTIGATOR_24057] (15 ≤ AHI ≤ 65) in adult patients who 
are not effectively treated by [CONTACT_24102]. The Inspi[INVESTIGATOR_24058] (Figure 1):  
 Inspi[INVESTIGATOR_24036], Model 3024 (Implantable Pulse Generator, IPG) and any 
subsequent iteration thereof that are approved under P130008 for the treatment of obstructive sleep 
apnea which are listed below and updated as needed via protocol modifications submi tted to the 
FDA.  Note: Inspir e Model 3028 IPG received FDA approval on May 5, 2017 and replaces Model 
3024 IPG.  
 Inspi[INVESTIGATOR_24038], Model 4063 (stimulation lead)  
 Inspi[INVESTIGATOR_24039], Model 4323 (sensing lead)  
 External programmers used with the system are:  
o Inspi[INVESTIGATOR_24040], Mo del 2740 (physician programmer)  
o Inspi[INVESTIGATOR_24041], Model 3032 (patient programmer)  
 
 
When the device  is on, the Inspi[INVESTIGATOR_24059]’s respi[INVESTIGATOR_24060].  
 
Device  settings are stored in the IPG and configured by [CONTACT_24103].  
The patient uses their Inspi[INVESTIGATOR_24061]. The sleep remote also p rovides the ability to pause therapy and adjust stimulation 
amplitude within physician defined limits.  
 
6.[ADDRESS_23150] of an Implantable Pulse Generator  (IPG), a 
respi[INVESTIGATOR_24062], and a stim ulation lead. All implanted Inspi[INVESTIGATOR_24063] -use only.  
6.1.1 Implantable Pulse Generator (IPG)  
The IPG (Figure 2) contains the battery and electronics that deliver Inspi[INVESTIGATOR_24064].  
 

  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 21 of 32  
 
The IPG has two 3.2 mm low -profile connector ports (Figure 3), which are compatible with the connectors 
on the stimulation lead and the respi[INVESTIGATOR_24062]. After inserting the lead connectors into the IPG 
connector ports, the lead connectors are secured using th e set screws next to the connector ports.  
 
 
Only study investigators will perform device implantation surgery. In order to become certified to implant the 
Inspi[INVESTIGATOR_24065], all participating surgeons will need to complete a training program, including cadav eric 
dissections, offered by [CONTACT_24084][INVESTIGATOR_24066].  This training program will also include modules on how the 
device is activated and programmed.    
 
Sleep medicine physicians and involved technicians will also complete training on device programming and 
titration based upon sleep study results.   
 
Using the physician programmer function on the device the general integrity of the system and subject use of 
the device can be verified.  The device will be interrogated at the 2 month, 6 month and 12 month visits, as 
well as at any unplanned visits.  Programming changes, difficulties operating the system, or any sudden 
changes in the system’s effects will be documented in the subject’s case file.  
 
Parents will be instructed on how to use the programmer to turn the device on/off and change settings by 
[CONTACT_24104], follow -up appointments, and during sleep studies.  
 
Any adverse events that o ccur during baseline or screening procedures will be documented on the Adverse 
Event Form and submitted for review.  
 
Refer to the System Implant Manual as well as the Patient Programmer Manual for details about the device, 
implant training, and system use.   
 

  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 22 of 32 6.2 Acquisition and accountability  
Each site will be authorized to begin enrolling subjects and order study devices once all appropriate regulatory 
documentation has been collected.  The study device s will be ordered based on each site’s study device 
accoun tability plan . The device s will not arrive labeled, as Inspi[INVESTIGATOR_24067].  
Each site must label the device “CAUTION – Investigation device. Limited by [CONTACT_4496] (or [LOCATION_002]) law 
to investigational use” and document t hat the device has been labeled appropriately.  
 
Devices must be stored in a secure (locked) area at room temperature. Access should be limited to designated 
study staff only. Device accountability logs will be provided to the site. It is the site’s respon sibility to 
document the receipt (including maintain shippi[INVESTIGATOR_24068]), disposition of the product (per subject use, including 
serial number of device used, serial number of remaining devices, etc.), transfer (if applicable) and return of 
all unopened study d evices.  This information mus t also be provided to the sponsor -investigator  for 
recordkeepi[INVESTIGATOR_24069].  
6.[ADDRESS_23151] Storage and Stability  
Inspi[INVESTIGATOR_24070] h ethylene oxide (EtO) prior to shipment.   
6.3.[ADDRESS_23152] the IPG ster ile package prior to opening. If the IPG package is damaged, the IPG may be damaged as 
well. Return a damaged package t o Inspi[INVESTIGATOR_24066].  The IPG box includes a sterilization indicator. 
This indicator is green after the device has been sterilized.  Do not use the IPG if the indicator is red.  
 
See Table 1 for IPG Storage and Handling  
 
Table 1. IPG Storage and Handling  
Handling and Storage: Acceptable  Unacceptable  
Store and transport IPG within the following 
environmental temperature limits: -35 °C  (-31 °F) 
to +58  °C (+136  °F). A full or partial electrical 
reset condition may occur at temperatures below -
18 °C (0 °F) Do not implant the IPG if it has been dropped on a 
hard surface from a height of 30 cm (12 in) or 
greater  
Resterilization   
The IPG cannot be resterilized.  
 IPGs cannot be resterilized. If the sterile 
package seal is broken, or if the packages 
are otherwise damaged, do not use.  
 Return the package to your local Inspi[INVESTIGATOR_24071], see back 
cover for address.   
 
6.3.2 Leads  
If the lead sterile package seal is broken or the package is otherwise damaged, return the package to Inspi[INVESTIGATOR_24072]. Leads cannot be resterilized.  
 
See Table 2 for Leads Storage, Handling, and Resterilization . 
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 23 of 32 Table 2. Lead Storage and Handling  
Handling and Storage: Acceptable  Unacceptable  
Store and transport leads within the following 
environmental temperature limits: -10 °C (14 °F) to 
+55 °C (131  °F).  
Only use sterile -gloved hands to handle the lead; 
rinse sterile surgical gloves in sterile water before 
handling the lead.  
Protect leads from materials that shed lint and dust.  
Exercise care and appropriate instrument selection 
when handling the stimulat ion lead cuff with a 
surgical instrument.  Do not implant a lead that was dropped  
Avoid excessive traction or sharp instruments  
Avoid severe bending, kinking, stretching, or 
handling with surgical instruments.  
Do not immerse a lead in mineral oil or silic one oil.  
Resterilization   
Leads cannot be resterilized.  
 If the sterile package seal is broken, or if 
the packages are otherwise damaged, do 
not use.  
 Return the package to your local Inspi[INVESTIGATOR_24071], see back 
cover of this manual for addresses.   
 
7 Risks and Benefits  
7.1 Known Potential Risks  
7.1.1 Risks of Screening Procedures  
[IP_ADDRESS]  Risks of Drug -Induced Sleep Endoscopy (DISE)  
 Nose bleeding  
 Trauma to the upper airway  
 Suspension of breathing epi[INVESTIGATOR_1865]  
 Light -headedness  
 Pain or irritation in the throat or nasal passage  
[IP_ADDRESS]  Risks of PSG Studies  
 Inability to sleep in the PSG lab  
 Irritation or bleeding at external electrode sites  
 Bruising or bleeding or soreness from external electrode removal  
 Fatigue the next day, loss of productivity  
 May lead to pain or sleeplessness  
 
7.1.[ADDRESS_23153] below the chin.  Normally this scar blends in wi th 
normal creases in the neck and is not disfiguring.  The electrodes and sensor should not be noticeable 
underneath the skin.  The stimulator may cause a small lump underneath the skin below the collar bone.  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23154] other neu rological causes of sleep apnea, called "central sleep apnea". If 
improvement in the subject’s OSA by [CONTACT_24105], 
additional treatment during and after his/her hospi[INVESTIGATOR_24073].  
 
[IP_ADDRESS]  Surgical  Related Risks  
 Post-surgical pain or tenderness near incisions  
 Post-surgical headache, fever, or dizziness  
 Post-surgical throat soreness from intubation  
 Post-surgical nausea or vomiting  
 Post-surgical irritability, nervousness, confusion   
 Post-surgical sleep problems like insomnia or sleepi[INVESTIGATOR_008]  
 Post-surgical constipation  
 Post-surgical mild to moderate swelling, oozing, and/or bruising around the surgical incisions,  
 Post-surgical back pain due to lying on the table during the procedure  
 Depending on geogra phy, standard uncomplicated post -implant hospi[INVESTIGATOR_24074] 36 
hours.   
 Damage to blood vessels (e.g. erosion) in the vicinity of implant  
 Allergic and/or rejection response to the implanted materials  
 Excessive bleeding  
 Infection  
 Trauma (e.g. pe rforation or dissection) or damage to arteries and veins  
 Local irritation, infection, seroma (pocket of clear fluid under the skin, hematoma (blood outside the 
blood vessels), erosion, swelling  
 Irritation or damage to nerves near the implant  
 Persistent pa in at the implant site  
 Nerve trauma  Pain, numbness or inflammation in the mouth, neck  
 Hypoglossal nerve trauma or damage  
 Strange sense of touch or burning sensation on the tongue or neck (dysesthesia)  
 Procedure related deterioration of pre -existing medic al condition  
 Tongue movement restrictions  
 Blood thinning medications may result in complications such as excessive bleeding, clotting, or 
hematomas  
 Tongue may get larger (hypertrophy) or smaller (atrophy)  
 Airway constriction or obstruction  
 Tongue muscle tw itches (Fasciculations)  
 Air in the chest cavity (pneumothorax)  
 Problems with swallowing or speaking  
 Damage to the lung or membrane that surrounds the lung (pleura)  
 Muscle stimulation of floor of mouth musculature  
 Death  Pneumothorax  
 
[IP_ADDRESS]  Risks of Anesthesia  
Drug induced sleep endoscopy, surgical implantation, battery replacement, electrode repositioning and device 
implantation will be performed under anesthesia.  General anesthesia can result in airway obstruction, 
temporary changes in heart -rate and oxygen l evel, and changes in behavior as medications wear off. These 
risks are increased in  subjects with Down syndrome.   
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 25 of 32  
[IP_ADDRESS]  Device Complications/Malfunctions  
 Migration or traction of pulse generator or leads   
 Elevated stimulation threshold  
 Lead dislodgement   
 Failu re to stimulate  
 Lead damage and/or failure   
 Implantable Pulse Generator failure  
 Premature battery failure   
 Failure of respi[INVESTIGATOR_24075]  
 Breakage or misuse of surgical tools   
 Misuse of the subject programmer may result in ineffective function  
 Spontaneou s stimulation and sensing threshold changes   
 Therapy may irritate a subject, wake them, or prevent them from sleepi[INVESTIGATOR_007]  
 MRI can induce currents on implantable components, potentially causing tissue damage and tongue 
dysfunction   
 MRI may cause damage to the device  
 Should your child become pregnant, there may be unknown risks to the embryo or fetus   
 There may be risks that are not currently known at this time  
 Implanted parts may need to be surgically moved or removed  
 
[IP_ADDRESS]  Potential Need for More Surgery  
Battery re placement: The implanted device is powered by a battery that has an expected lifespan of [ADDRESS_23155]’s device. Although unlikely, the battery may deplete sooner than expected.  Battery 
replacement is performed through a small incision at the device implant site below the subject’s collar bone 
under local anesthesia, where a numbing medication is injected into the tissue over the implant.    
 
Repositioning or replacement of stimulation or sensing leads: If one of the implanted leads moves, the 
investigator may need to perform another surgery to reposition or replace the lead in order for the subject to 
continue to use the device.  Risks related to another surgery are described in the potential risk section (table), 
as well as sections on considerations for implanted device removal and potential risks associated with 
implanted device removal.  
 
7.1.3 Pregnancy Risks  
A female subjects may not take part in the study if she is pregnant or has plans  to become pregnant during 
the study period due to procedures that require general anesthesia.  All female subjects aged 11 and up will 
undergo urine beta -HCG testing on the day o f procedures requiring general anesthesia (DISE, implantation, 
and any other unanticipated surgical procedures related to implantation).  Subjects who are positive will not 
undergo surgical implantation or procedures under general anesthesia.  
 
7.1.4 Psychosocial  (non -medical) Risks  
Subjects may experience distress regarding discomfort from the surgery or device.  
 
7.1.5 Considerations for Future Medical Care  
Strong magnetic fields generated by [CONTACT_9252] (MRI) scanners may move the stimulation 
device, l eads, or cause excessive stimulation .  After the device is implanted, the subject will not be able 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23156], the Inspi[INVESTIGATOR_1312]® system must be removed surgically.   
 
Precautions must be taken around theft and security detectors (such as those found in museums, retail stores, 
courthouses, and airports).  The magnetic fields created by [CONTACT_24106]’s tongue.  In rare cases, they could also reset the devi ce to zero volts.  If this 
happened, it would become clear the next time the subject tried to use the device. When the remote is 
positioned above the subject, it will beep if the device is working properly; it will not beep if the device has 
been reset to zero volts.   Should the device be reset , the subject will need to see the doctor to have the device 
reprogrammed.  
During the course of the subject’s life, additional implantable devices such as cardiac defibrillators or 
pacemakers may need to be placed.  T he nerve stimulator might interfere with functioning of these devices.  
Therefore, it is important that any doctor taking care of the subject know about the nerve stimulator that is 
implanted.  The treating doctor should contact [CONTACT_24107]’s implanted device remains safe.  
 
A wallet card and laminated letter will be provided to subjects identifying them as having this implant.  
Written instructions will be provided to families detailing im portant information dentists and other surgeons 
should know when providing medical care to the subject.  
 
7.[ADDRESS_23157] (DSMB) will serve as the independent data and safety monitoring 
board for this study. The DSMB will meet regularly as laid out in the DSMB charter to review progress  of the 
study and will be available for emergent meetings if serious or unanticipated adverse events occur. The 
serious adverse events and responses will be reviewed by [CONTACT_4318].  
8.2 Research monitor  
The chair of the DSMB will also serve as the Research Monito r. The Research Monitor will review all 
unanticipated problems involving risks to subjects or others associated with the protocol and provide an 
independent report of the event to the IRB. The Research Monitor may discuss the research protocol with 
the inv estigators; shall have authority to stop a research protocol in progress, remove individual human 
subjects from a research protocol, and take whatever steps are necessary to protect the safety and well -being 
of human subjects until the IRB can assess the m onitor's report; and shall have the responsibility to promptly 
report their observations and findings to the IRB or the Data Safety and Monitoring Board (DSMB).  
8.3 Regular Site Monitoring  
An external monitor will be contracted by [CONTACT_456] -investigator to do on site monitoring. This monitoring 
will be done at regular intervals as outlined by [CONTACT_24108], regulations, and guidelines.  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 27 of 32 8.4 Adverse Event Monitoring and Repo rting  
All adverse events (AEs) will be documented in a timely manner throughout the clinical trial and reported in 
the database.  All events will be reported to the PI, FDA, and DSMB. The s ponsor -investigator  has 
established procedures in conformity with worldwide regulatory requirements to ensure appropriate reporting 
of safety information.  This study is conducted in accordance with these procedures and regulations.  All 
adverse events and adverse device effects will be reported in all geographies.  Repo rtable adverse events will 
be monitored prospectively from enrollment (consent) to the end of the follow -up period. For the purposes 
of this study, reportable AEs include all events meeting the definition of “serious” as well as any 
events possibly related to the study procedures, study device, therapy o r required testing. See Figure 
4 (Classification of Adverse Events) to determine whether in AE is reportable.  
 
8.4.1 AE Definitions for Investigator Classification  
Investigators are respons ible for categorizing adverse events according to their seriousness and relatedness 
(e.g., to the surgical procedure, to the Inspi[INVESTIGATOR_24076], etc.) .  The Sponsor will then review all reported adverse 
events for completeness, and ask for clarification or add itional information if necessary.  The definitions for 
classifications are included below and on the provided adverse event log .  Those events that do not meet the 
criteria for Serious Adverse Event are considered non -serious.  
 
[IP_ADDRESS]  Adverse Event  
An Adverse Ev ent (AE) is any undesirable subject event that occurs during the course of the study, from 
consent through exit.  For the purpose of the study, reportable AEs include all events meeting the definition 
of “serious” as well as any events possibly related to the study procedure, study device, therapy or required 
study testing.  
 
[IP_ADDRESS]  Serious Adverse Event  
Serious AEs will be identified as such on the AE CRF and defined as any adverse experience that results in 
any of the following outcomes:   
 Death  
 A life -threaten ing adverse experience  
 In-patient hospi[INVESTIGATOR_1081]  
 A persistent or significant disability/incapacity  
 Congenital anomaly/birth defect  
 Important medical events that may not meet one of the above definitions could be  considered SAEs 
if they jeopardize the health of the subject or require surgical intervention to prevent one of the 
outcomes listed in the definition above.  Serious adverse events may or may not be related to the 
procedure, system or therapy.  
 
[IP_ADDRESS]  Unanticip ated Adverse Device Effect  
An unanticipated adverse device effect (UADE) is any event on the subjects’ health, safety, or welfare not 
previously identified in nature, severity, or degree of incidence in the investigator’s brochure and 
investigational plan .  A serious device -related AE which is not identified as a potential complication in the 
labelling, and is unanticipated, adverse, and a consequence of the use of the Inspi[INVESTIGATOR_24030], must be reported 
to the sponsor  as soon as possible, but in no case great er than five working days from the first  knowledge of 
the occurrence.  The sponsor -investigator  will coordinate with the site Investigator on the submission of 
specific clinical documentation appropriate to the UADE encountered.  In addition, written notic e must also 
be supplied to the sponsor and reviewing IRB within 10 working days.  
 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23158].  A 
terminated investigation may not be resumed without IRB approval.  
 
8.4.2 Adverse Event Reporting  
All procedure and device related events will be collected during this study.  In addition, all adverse events 
meeting the definition of ‘serious’ (Section 10.12) are required to be reported.  All reportable adverse events 
are to be recorded on the AE CRF at the time of the occurrence(s) or at the time the Investigator becomes 
aware of the occurrence(s).  Additional information, such as procedural notes, oper ative notes, or a signed 
clinical summary may be required as supporting documentation for the reported AE.  All identifying 
information should be removed from these supportive documents and the subject’s study number should be 
used.  
 
All adverse events mus t also be described by: [CONTACT_24109] (onset and resolution dates); severity; relationship to 
the procedure, device or therapy; action taken to resolve the event; the outcome of the event and if it meets 
the definition of ‘serious’.  In addition a code will be assigned to the event based on type of relationship 
determined.  Relationship categories and codes are described below. All adverse events should be followed 
until the adverse event has been resolved, the subject has reached maximum medical improvement wit h no 
further actions to be taken, the subject exits the study, or until study closure, whichever occurs first.  
 
The timeframe for reporting of serious or unexpected AE’s to the Sponsor and governing IRB is presented in 
the table below  (Table 3 ):  
 
Table 3:  Reporting requirements and Timeframe for SAEs and UADEs  
Type of AE  Reporting Timeframe  
SAE Notify sponsor -investigator  as soon as possible, with full 
report no later than 10 working days of occurrence or sites 
knowledge  
UADE  Notify sponsor -investigator  as soon as possible, with full 
report no later than 10 working days of occurrence or sites 
knowledge  
Death  Notify sponsor -investigator within 24 hours  
 
[IP_ADDRESS]  Relationship  
Investigators are also responsible to categorize adverse events according to their relat edness.  The definitions 
for relatedness classifications are included below.   
 
[IP_ADDRESS].1  Surgery Related  
A surgical related adverse event is any adverse event that is related to or possibly related to the surgical 
procedure to implant the device. These events typic ally occur within 30 days of surgery. Examples include 
significant bleeding during surgery, infection, acute tongue weakness.  
 
Any normal and expected postoperative complaints or symptoms are not required to be reported, unless the 
event involves a clinic ally significant change in severity or duration of symptoms or requires clinical 
intervention that is different from ordinary postoperative care. Expected postoperative care outcomes 
include: headache, incisional pain, nausea, vomiting, low grade fever, oo zing at dressing, dizziness, irritability, 
nervousness, temporary sleep problems like insomnia or sleepi[INVESTIGATOR_008], constipation, confusion and similar 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 29 of 32 events, tenderness, throat soreness secondary to intubation, or mild to moderate swelling and/or bruising 
around the implant site, back pain due to lying on the table during the procedure.  
 
[IP_ADDRESS].2  Device Related  
A device related adverse event is any adverse event that is related or possibly related to use of the device. 
Examples include device -related injection, undesirable change in stimulation (e.g. jolting or shocking), chronic 
or intermittent tongue soreness, discomfort, or intense stimulation. Acute events that occur during a device 
check that subside once acceptable parameters are selected are not reportable.  
 
[IP_ADDRESS].3  Other Protocol Testing or Evaluation Related  
Other procedures required as part of the study protoco l but not associated with an Inspi[INVESTIGATOR_24077], that result in an AE.  Examples include: sore neck from in -lab PSG; nausea from anesthesia 
during DISE, etc.  
 
[IP_ADDRESS]  Degree of Intensity / Severity  
In addition, investigators will categorize t he intensity / severity of all AEs CRF as:  
Mild:   Awareness of event, but easily tolerated  
Moderate:   Discomfort enough to cause interference with usual activity  
Severe:    Inability to carry out usual activity  
This determination is distinct and separate from the determination of whether or not an event is an adverse 
event (AE) or a serious adverse event (SAE).  
 
8.4.3 Anticipated Adverse Device -Related Events  
Anticipated device related AEs (medical change from baseline), which may possibly be seen during this st udy, 
include the following presented in Table 4 (below), as reported in the PMA submission for 126 implanted 
subjects.  
 
Table 4:  Anticipated Adverse Device -Related Events  
Adverse Event  Total Number 
of Events  % of Subjects 
(n) 
N=126  
Discomfort due to electrical stimulation  66 33% (42)  
Temporary Tongue weakness or 
deviation  35 18% (23)  
Tongue abrasion  23 16% (20)  
Mechanical pain associated with presence 
of device  6 5% (6)  
Infection (mild or moderate)  1 1% (1)  
 
8.4.4 Technical Observation/Device Deficiencies  
All device deficiencies related to the identity, quality, durability, reliability, safety, or performance of an 
investigational device shall be documented throughout the investigation.  Device deficiencies that did not lead 
to an adverse event  but could have led to a medical occurrence shall be reported including if suitable action 
had not been taken, intervention had not been made, or circumstances had been less fortunate.  
 
User Error : An instance where an act or omission of an act results in a different medical device response 
than intended by [CONTACT_24110] a ‘user error’.  This includes slips, 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23159] include a detailed narrative that provides detailed information describing the circumstances surrounding 
the death and is si gned by [CONTACT_079] [INVESTIGATOR_24078] -Investigator.  The death letter should 
include the following information:  
 Date and time of death  
 Place death occurred  
 Immediate cause of death  
 The relatedness of the death to the Inspi[INVESTIGATOR_24030], surgical  procedure, neurostimulation, clinical 
investigation, or subject condition.  
 Whether or not the death was witnessed  
 Device status and/or activity at the time of death  
 Any other circumstances surrounding the death  
 
The PI [INVESTIGATOR_5768] -Investigator must sign and da te the letter.  If information listed above that is unavailable or 
unknown must be specified in the death letter. Also the following documentation should be obtained:  
 If the subject expi[INVESTIGATOR_24079], a copy of the medical records for that admission (e.g., H & P, 
consults, test results, operative reports, and/or progress notes from the hospi[INVESTIGATOR_3853])  
 Death certificate (if available)  
 Autopsy report (if applicable)  
 
The study exit CRF will be completed and any open events will be formally closed in the  database (outcome: 
death).  Whenever possible, the pulse generator should be interrogated. Study devices and related Sponsor 
system components (e.g., leads) should be removed intact and returned promptly to Sponsor for analysis.   
 
9 Statistical Considerati ons  
9.1 Primary endpoint(s) or outcome measure(s)  
 The primary endpoint of this pi[INVESTIGATOR_24080].  
 Safety of implantation  will be monitored throughout the perioperative period and unanticipated and 
anticipated adverse device related events will be recorded.  
9.2 Secondary endpoints or outcome measure(s)  
 The secondary endpoint of this study is to assess the efficacy of hypoglossal  nerve stimulator 
placement in this patient population.  
 Effectiveness in the treatment of obstructive sleep apnea will be measured using standard in -lab PSG 
measures, including oxygen level, partial and complete airway obstruction, and arousals.  
Improveme nt will be defined as a 50% or more decrease in AHI.  This will be measured prior to 
implantation, and compared to post -implantation values at 2 months, 6 months, and 12 months.  
 Compliance will be assessed by [CONTACT_24111], which wi ll be downloaded 
using the physician programming function at follow -up visits.  
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; 08 May 2020  Page 31 of 32  Quality of life improvements will also be measured using the OSA -18 questionnaire and Epsworth 
Sleepi[INVESTIGATOR_7110].  Assessments will be performed preoperatively then at 2 months, 6 months, and 12 
months.  
9.3 Sample Size Determination  
This is a pi[INVESTIGATOR_24081] s yndrome. Up to for ty-two (42) adolescents and young adults will u ndergo 
implantation for this study.  If implantation can be safely performed in this population, further studies will be 
designed and powered to assess for significant changes on PSG and quality of life with device usage.  
9.4 Analysis Population  
The pi[INVESTIGATOR_24082] a preliminary efficacy study and will be utilized in the 
statistical evaluation of study endpoints.  
9.5 Effectiveness Analysis (if applicable)  
 Pre and post -implantation quality of life scores and polysomnogram values will b e used to assess the 
effectiveness of hypoglossal nerve implantation in the treatment of obstructive sleep apnea in 
adolescents with Down Syndrome.  
 Any deviations from the previously described statistical plan will be described and justified in a 
protocol  amendment and/or in the final report submitted to this application.  
9.[ADDRESS_23160] population. Both parents/guardians of the potential subject will be consented unless  one parent is 
deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal 
responsibility for the care and custody of the child. . Of note, it is possible that one parent may not be 
reasonably available due to inability to travel to a study site based on financial restrictions or other logistical 
concerns such as childcare for other children, job requirements, etc. In such cases, both parents will discuss 
the study with the local PI [INVESTIGATOR_24083], along with the reason 
that one parent will not be available to sign consent in person on the day of consent.  
 
Additionally, the underage subject themselves will also be assen ted. Written assent is preferred, but verbal 
assent will be obtained and documented in cases where the subject’s maturity and/or ability make obtaining 
written consent infeasible. If the underage subject turns [ADDRESS_23161] turns 18 and is not capable of 
  Pediatric HGN Study  
  Protocol: 14 -146H  
v. 9.5; [ADDRESS_23162] is deemed incapable of 
providing consent, two parent/guardian consent and subject assent will be obtained as with  pediatric subjects 
on this trial.  
10.2.[ADDRESS_23163] ap plicability of our results to 
the general population, nor should it prevent all qualified patients from eventual access to device 
implantation.  
10.3 Statement of Compliance  
This study will be performed in compliance with all applicable federal, state, and loca l regulations and 
requirements for the protection of human subjects in a clinical trial.  
References  
(1) Diercks GR, Keamy D, Kinane TB, et al. Hypoglossal Nerve Stimulator Implantation in an 
Adolescent With Down Syndrome and Sleep Apnea. Pediatrics. 2016;137 (5):e20153663  
(2) Diercks GR, Wentland C, Keamy D, et al. Hypoglossal Nerve Stimulation in Adolescents With 
Down Syndrome and Obstructive Sleep Apnea. JAMA Otolaryngol Head Neck Surg. 
2018;144(1):37 –42. doi:10.1001/jamaoto.2017.1871  
(3) Caloway, C. L., Diercks, G.  R., Keamy, D. , de Guzman, V. , Soose, R. , Raol, N. , Shott, S. R., 
Ishman, S. L. and Hartnick, C. J. (2019), Update on hypoglossal nerve stimulation in children with 
down syndrome and obstructive sleep apnea. The Laryngoscope. doi:10.1002/lary.[ZIP_CODE] \ 
(4) Johns MW, A New Method for Measuring Daytime Sleepi[INVESTIGATOR_008]: The Epworth Sleepi[INVESTIGATOR_7110]. Sleep, 
14(6):540 -545. 
(5) Franco RA Jr, Rosenfeld RM, RaoM. Quality of life for children with obstructive sleep apnea. 
Otolaryngol Head Neck Surg. 2000;123(1, pt 1):9 -16. 
(6) Iber C, Ancoli -Israel S, Chesson A, Quan SF for the American Academy of Sleep Medicine.  The 
AASM Manual for the Scoring of Sleep and Associated Events:  Rules, Terminology and Technical 
Specifications, 1st ed.:  Westchester, Illinois:  American Academy of Sle ep Medicine, 2007.  
 